Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular Therapies
Open Access
- 12 July 2017
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 745
- https://doi.org/10.3389/fimmu.2017.00745
Abstract
Immunotherapies based on NK cells are among the most promising therapies under development for the treatment of so far incurable forms of leukemia and other types of cancer. The importance of NK cells for the control of viral infections and cancer is supported among others by the findings that viruses and tumors use a multitude of mechanisms to subvert and evade the NK cell system. Infections and malignant diseases can further lead to the shaping of NK cell populations with altered reactivity. Counter measures of potential therapeutic impact include the blocking of inhibitory interactions between NK cell receptors and their cellular ligands, the enhancement of activating receptor signals and the infusion of large numbers of ex vivo generated and selected NK cells. Moreover, the specific cross-linking of NK cells to their target cells using chimeric antigen receptors or therapeutic bi-/tri-specific antibody reagents is a promising approach. In this context, NK cells stand out by their positive effects and safety demonstrated in most clinical trials so far. Based in part on results of the recent EC-sponsored project "NATURIMMUN" and considering additional published work in the field, we discuss below new developments and future directions that have the potential to further advance and establish NK cell-based therapies at the clinics on a broader scale.Funding Information
- European Commission (FP7-MC-ITN-317013-NATURIMMUN)
This publication has 57 references indexed in Scilit:
- In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal CancerFrontiers in Immunology, 2017
- Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal CancerPLOS ONE, 2016
- Advances in clinical NK cell studies: Donor selection, manufacturing and quality controlOncoImmunology, 2015
- Harnessing adaptive natural killer cells in cancer immunotherapyMolecular Oncology, 2015
- Advantages and applications of CAR-expressing natural killer cellsFrontiers in Pharmacology, 2015
- CD19-CAR TrialsThe Cancer Journal, 2014
- IL-12 Directs Further Maturation of Ex Vivo Differentiated NK Cells with Improved Therapeutic PotentialPLOS ONE, 2014
- Dendritic Cell Editing by Activated Natural Killer Cells Results in a More Protective Cancer-Specific Immune ResponsePLOS ONE, 2012
- NK cells at the interface between innate and adaptive immunityCell Death & Differentiation, 2007
- Imprint of human cytomegalovirus infection on the NK cell receptor repertoireBlood, 2004